Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 3.99B 3.75B 3.43B 6.41B 436B 6.46B 45.09B 17.48B 222B 17.09B 16.71B 720B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.12B 3.88B 3.54B 6.62B 450B 6.67B 46.56B 18.05B 229B 17.65B 17.26B 744B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+0.49%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.68
Extreme 7.68
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap. Importance
27/04/26 Issuer sale

General Counsel

1,264,993 0.4029%
27/04/26 Issuer sale

Director

395,940 0.1261%
27/04/26 Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+77.57%+18.19% 4.55B
-0.18%+4.35%+4.23%+31.79% 47.86B
-0.83%-0.36%+43.66%+34.77% 44.46B
-0.84%+4.86%+10.92%+91.52% 41.85B
-1.10%-2.64%+331.49%+535.80% 41.34B
-0.62%+0.11%+1.12%+46.02% 30.04B
-2.07%+0.12%+24.39%+154.30% 17.59B
-3.55%+1.95%+21.97%+38.83% 15.69B
-6.08%-9.92% - - 15.6B
-0.78%+9.46%-8.96% - 13.93B
Average -1.49%+1.54%+56.27%+118.90% 27.29B
Weighted average by Cap. -1.09%+1.31%+67.39%+139.02%

Financials

2024 2025
Net sales 528M 464M 436M 398M 745M 50.61B 750M 5.24B 2.03B 25.8B 1.98B 1.94B 83.65B 634M 557M 523M 478M 894M 60.75B 901M 6.28B 2.44B 30.97B 2.38B 2.33B 100B
Net income -56.11M -49.24M -46.29M -42.32M -79.08M -5.37B -79.67M -556M -216M -2.74B -211M -206M -8.88B -27.11M -23.79M -22.37M -20.45M -38.21M -2.6B -38.5M -269M -104M -1.32B -102M -99.58M -4.29B
Net Debt 194M 170M 160M 146M 273M 18.55B 275M 1.92B 744M 9.46B 727M 711M 30.67B 149M 131M 123M 112M 210M 14.26B 211M 1.47B 572M 7.27B 559M 547M 23.57B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock